Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Early voting for NC primary runoff; Election Day is May 14
Recommended
End-of-grade tests: Everything you need to know about these annual exams
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
8.780
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
450
Open
8.780
Bid (Size)
8.340 (1)
Ask (Size)
8.780 (1)
Prev. Close
8.780
Today's Range
8.780 - 8.780
52wk Range
1.760 - 15.21
Shares Outstanding
50,241,789
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
April 12, 2024
Via
Benzinga
Performance
YTD
+155.98%
+155.98%
1 Month
-9.30%
-9.30%
3 Month
+44.88%
+44.88%
6 Month
+281.74%
+281.74%
1 Year
-38.99%
-38.99%
More News
Read More
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
February 28, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
February 09, 2024
Via
Investor Brand Network
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Proposed Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 01, 2024
Via
Benzinga
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday
January 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.